Leader in home data analysis, the Lausanne-based start-up DomoSafety offers a remote medical detection and monitoring service. In their new collaboration with Roche Pharma, they are launching a pilot project to improve the lives of people suffering from neuromuscular diseases using digital health technologies.
Announced yesterday, this partnership between DomoSafety Ltd and Roche Pharma (Switzerland) Ltd aims to improve the quality of life of patients suffering from Spinal Muscular Atrophy (SMA), a rare neuromuscular disease. Anne Marquet, SMA Rare Conditions Partner for Switzerland at Roche, said: “We look forward to leveraging DomoSafety’s approach to bring innovative solutions to the needs of SMA patients and are thrilled to work with SMA Schweiz and with the whole SMA community to co-create the best solutions for patients, families and caregivers and for the medical team looking after them. I believe our partnership with DomoSafety will pave the way for new solutions to some of the most important needs of people living with SMA”.
For people living with SMA, like many people with chronic conditions, digital health technologies bear the potential to monitor disease progression in real-life, continuously and in a holistic manner, and to provide solutions to support people in living an independent life and feeling safer and freer, at home and on the go.
As part of their collaboration, Roche is supporting a project during which DomoSafety will adapt its evolutive platform to the needs of SMA patients. It will take the form of a private cloud platform which will aggregate information available from multiple sources such as smartwatches, IoT (Internet of Things) platform or medical devices. Patients will have access to their data in real-time through a mobile application, allowing them to monitor and potentially optimize their care and well-being, and alerts will be proactively or automatically triggered in case of an emergency.
Guillaume DuPasquier, CEO of DomoSafety added: “We are very excited to partner with Roche and explore solutions to improve the lives of patients with this rare disease. We look forward to adapting our tools to the needs of patients with SMA and improving their quality of life.” In fact, DomoSafety’s AI and Maching Learning technologies have the potential to really improve the care of SMA patients, by predicting or detecting early potential sudden health deteriorations. Their algorithms will be matching billions of behavioural and physiological data points collected during multiple clinical research studies conducted in collaboration with several Swiss university hospitals, such as CHUV, Lausanne and Inselspital, Bern, and internationally renowned institutes (EPFL, Lausanne and a bioengineering lab of Bern University).
>> Discover DomoSafety : www.domo-safety.com
>> Read the full press release : PressRelease_20210501_final_clean_EN